StockData
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR) company profile

ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.84−0.03 (-3.91%)

Close on Nov 17, 2026Market cap $13.38MP/E –Yield –

About Allarity Therapeutics

Pharmaceutical Preparations, SIC 2834

Allarity Therapeutics is a clinical-stage precision medicine pharmaceutical company developing targeted cancer therapeutics. The company focuses on its lead therapeutic candidate, stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) and tankyrases being evaluated in clinical trials for advanced ovarian cancer and relapsed small cell lung cancer. In conjunction with drug development, the business utilizes its proprietary Drug Response Predictor (DRP) companion diagnostic platform to identify patients most likely to benefit from specific treatments. It also provides DRP analysis and gene expression laboratory services to external biotechnology clients.

The company operates its clinical research across trial sites located in the United States and Europe. It also maintains external out-licensing and development partnerships, including collaboration with Chosa Oncology. Allarity Therapeutics maintains its principal executive offices in Tarpon Springs, Florida.

Summary of the business section of Allarity Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Allarity Therapeutics, Inc.
Founded
2004
Headquarters
Boston, MA
Address
24 School St., 2nd Floor 02108
Phone
(401) 426-4664
Employees
8, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Wolf & Company P.C., Boston, Massachusetts

Stock & identifiers

Ticker
ALLR
Exchange
Nasdaq
IPO date
Dec 21, 2021
Shares outstanding
16M, Aug 14, 2026
Public float
$14.73M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-30 reverse, Sep 11, 2024; 1-for-20 reverse, Apr 9, 2024; 1-for-40 reverse, Jun 29, 2023; 1-for-35 reverse, Mar 27, 2023
SEC CIK
1860657
CUSIP
016744500
ISIN
US0167445008
FIGI
BBG012NXCZP8
Share class FIGI
BBG012NXCZQ7
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeremy R. GraffSee Remarks80,095
Thomas JensenCEO596,734
Jeffrey S. ErvinCFO150,000
Alexander EpshinskyCFO85,051
Jesper HoeilandDirector25,000
Gerald W. McLaughlinDirector70,000
Laura BenjaminDirector–
Joseph Walter VazzanoDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Thomas H. Jensen
Chief Executive Officer
$647.38K$355.50K$400.70K$55.37K$1.46M+84%
Jeffrey S. Ervin
Chief Financial Officer
$119.62K$35.98K–$2.93K$158.53K–
Jeremy R. Graff
President and Chief Development Officer
$494.00K$222.30K$145.89K$46.63K$908.82K+75%
Steen Knudsen
Chief Scientific Officer
$168.35K$68.45K––$236.80K+20%
Alexander Epshinsky
Former Chief Financial Officer
$176.80K––$206.75K$383.55K+10%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had eight employees; seven of whom were full-time and one part-time.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 14, 2025Late filingNotification of late filing
Jun 21, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 17, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 30, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 27, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 26, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 12, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 10, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 6, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 23, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 21, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 25, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 14, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 12, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 26, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 24, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 15, 2022Late filingNotification of late filing
Aug 12, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
May 17, 2022Late filingNotification of late filing
Apr 22, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2022Late filingNotification of late filing
Dec 22, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 22, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 13, 2021ListingRegistration of securities on an exchange (Form 8-A)
Aug 20, 2021MergerRegistration of securities for a merger or exchange offer (S-4)

See a number that looks wrong?